Introduction: Prostatic carcinoma is a common cause of morbidity and mortality in men worldwide. Gleason score is the most accepted method of grading Prostatic carcinoma. At times it is difficult to determine Gleason score which is partially subjective. Ki -67 expression in Prostatic carcinoma has shown correlation with Gleason score. This study is designed to evaluate whether the Ki-67 proliferation marker labelling index can be useful in determining the grade of Prostatic carcinoma using routine histology as gold standard.

Methods: 54 cases of adenocarcinoma prostate having adequate tissue available for immunohistochem-istry was included in the study. 4 micrometer thick sections were obtained for H&E and immunohistochemical staining with MIB 1 – following antigen retrieval.

Results: All the prostatic carcinoma cases studied are acinar adenocarcinomas. The most common age group is between 61-70 years.  Majority of patients have a Gleason score of 7 (40.7%) and grade group 5 (37%). The mean Ki67 labelling index in low grade tumours is 17.3% and in high grade tumours is 55.1%. Ki67 LI in low grade tumours is between 0-30% and in high grade tumours is >30% and thus a value of 30% is used as a cut off to discriminate the two.

Conclusion: The findings of the study indicate that Ki67 labelling of needle biopsy of prostate can be used as an additional diagnostic parameter for differentiating between low and high grade prostatic carcinoma. This may be useful in the clinical management of these patients. It could help in determining the subset of patients having favourable prognosis and also identify those who  might benefit from Active surveillance.

Keywords: Gleason score (GS); Ki67labelling index (Ki67LI); Prostatic carcinoma; grading.

1. Rugwizangoga B, Vuhahula E et al. A combination of Ki67 expression and Gleason score for prostatic adenocar-cinoma offers better prognostic information than either alone. The Internet Journal of Urology 2014 Vol. 12 No 1.
2. Iemelynova A.A., Grygorenko V.M. et al. Correlation between histological type and immunohistochemical profile of prostate cancer and Gleason scale gradation. Exp Oncol 2009 31, 4 , 246-249.
3. Diaz JI, Mora LB , Austin P F et al . Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation. Urology 1999; 53 : 931-938.
4. Epstein JI, Zelefsky MJ, Sjoberg DD, et A contemporary prostate cancer grading system: a validated alternative to Gleason score. EurUrol. 2015.
5. Liang Cheng et al. Cell proliferation in prostate cancer patients with lymph node metastasis : a marker for progression. Clin Cancer Res 1999;5:2820-2823.
6. Peter A. Humphrey, Holger Moch , Antonio L. Cubilla, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours EUROPEAN UROLOGY 2016 ;70:106 – 119.
7. Gleason DF, Mellinger GTThe Veterans Administration Cooperative Urological Research Group: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.   J Urol   1974; 111:58-64.
8. Borre M, Bentzen SM, Nerstrøm B, Jens  Overgaard J. Tumour cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol 1998;169: 1609-1614.
9. Mwakyoma HA, Magandi JL. Correlation of Gleason’s score and pretreatment PSA in prostate cancer patients. Professional Med J Jun 2010;17(2):235-240.
10. Abern MR, Bassett MR, Tsivian M et al. Race is associated with discontinuation of active surveillance of low-risk prostate  cancer: Results from the Duke Prostate Center," Prostate Cancer and  Prostatic Disease 2013;16:84-89. 
11. Delahunt B, Miller RJ, Srigley JR, Evans AJ, Samaratunga H. Gleason grading: past, present and future. Histopathology 2012;60:75–86.
12. Falzarano SM, Magi-Galluzzi C. Prostate Cancer Staging and  Grading at Radical Prostatectomy Over Time.  AdvAnatPathol 2011;18:159–164.
13. Mosse CA, Magi-Galluzzi C, Tsuzuki T,  Epstein JI:  The prognostic significance of tertiary Gleason pattern 5 in  radical prostatectomy specimens. Am J Surg Pathol   2004; 28:394-398

Dr Nimmy Cyriac

Analil House, Uzhavoor P.O., Kottayam District, Kerala – 686634, India

Phone- 9495351076, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.